NSECertificate under SEBI (Depositories and Participants) Regulations, 201812 Oct 2026 · 12 Oct 2026, 04:31 pm
Certificate under SEBI (Depositories and Participants) Regulations, 2018
GlaxoSmithKline Pharmaceuticals Limited · GLAXO
✦ AI Summary
GlaxoSmithKline Pharmaceuticals Limited has submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialization of securities and listing of new certificates on stock exchanges.
Analysis Scores
Earnings Impact0/10
Growth Catalyst0/10
Governance Concern0/10
Regulatory Risk0/10
Balance Sheet Risk0/10
Liquidity Impact0/10
Market Sentiment0/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Attachments (1)
📄pdf
Download →
GLAXO1924_12102026163134_clause_74.pdf
View document text
GlaxoSmithKline Pharmaceuticals Limited
GSK House, Dr. Annie Besant Road,
Worli, Mumbai - 400 030
Tel No: +91 22 2495 9595
Fax No: +91 22 2495 9494
Web: www.gsk-india.com
Email: askus@gsk.com
12th October 2026
BSE LIMITED THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Phiroze Jeejeebhoy Towers Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Dalal Street Bandra-Kurla Complex, Bandra (East)
Mumbai - 400001 Mumbai - 400051
Dear Sir,
Sub: Certificate pursuant to Regulation 74(5) of SEBI (Depositories and
Participants) Regulations, 2018 for the quarter ended 30th September 2026
In Compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations,
2018, please find enclosed herewith a copy of the Certificate received from Kfin Technologies
Limited, the Registrar and share Transfer Agent of the Company, for the quarter ended
30th September 2026.
Kindly take the above intimation on your records.
Thanking you
Yours faithfully
For GlaxoSmithKline Pharmaceuticals Limited
Ajay Nadkarni
Vice President – Administration, Real Estate
& Company Secretary
Encl:
CIN: L24239MH1924PLC001151
KFIN/CERT/74(5)/SEPT/2026
Date: 08/10/2026
The Company Secretary
GlaxoSmithKline Pharmaceuticals Limited
Dr. Annie Besant Road
Worli, Mumbai-400030.
Dear Sir(s),
Sub: Certificate under Regulation 74(5) for the quarter ended September 30, 2026.
Pursuant to Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018,
we hereby confirm that the securities received from the depository participants for dematerialisation during the quarter
ended September 30, 2026, were confirmed (accepted / rejected) to the depositories by us and the securities comprised
in the said certificates have been listed on stock exchanges where the earlier issued securities are listed.
We also hereby confirm that the security certificates received for dematerialisation have been mutilated and cancelled
after due verification by the depository participant and the name of the depositories have been substituted in register of
members as the registered owner within 30 days.
Request to kindly take the above on record.
Thanking you,
Yours faithfully,
For KFin Technologies Limited
Dnyanesh Gharote
Vice President